Drugs / BP101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03102489 | Feb → Jun 2017 | hypoactive sexual desire disorder | Ivix LLX | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03080298 | Mar 2016 → Apr 2017 | hypoactive sexual desire disorder | Ivix LLX | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03463707 | Mar → Nov 2018 | hypoactive sexual desire disorder, physiological sexual disorder | Ivix LLX | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BP101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03463707 ↗ |
| Route | Intranasal | “Nasal spray” NCT03102489 ↗ |